Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?

• Paula Rodriguez-Otero,
• Joana Reis,
• Ana Alfonso-Pierola,
• Diego Salas-Benito,
• Miriam Giraldez,
• Jose Ramón Azanza,
• Mariano Ponz-Sarvise

Affiliations

Paula Rodriguez-Otero

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Joana Reis

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Ana Alfonso-Pierola

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Diego Salas-Benito

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Miriam Giraldez

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Jose Ramón Azanza

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Mariano Ponz-Sarvise

Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain